Paul Ruff

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.

Marc Peeters, Tae Won Kim, P. Ruff, 2014, The Lancet. Oncology.

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Josep Tabernero, Jean-Yves Douillard, David Cunningham, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Jianying Zhou, Erdem Goker, Jun Zhao, 2019, The Lancet.

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).

Scott D. Patterson, Josep Tabernero, Jean-Yves Douillard, 2013 .